Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

Anandamide (AEA)

Our opinion on this compoundNiche research probe

46/100

Canonical endocannabinoid reference probe, irreplaceable in assays but impractical as an administered compound

Anandamide occupies a strange position in the research compound library. It’s genuinely foundational. Devane and Mechoulam’s 1992 Nature paper establishing AEA as the first identified endocannabinoid is one of the landmark papers of modern neuropharmacology, and the on-demand synthesis/degradation model it revealed changed how we think about retrograde synaptic signaling entirely. We have a lot of respect for what this molecule did for the field. That’s not why it’s here.

The scoring problem with AEA is the gap between its biological importance and its utility as an investigator-administered compound. Plasma half-life on the order of minutes, driven by FAAH-mediated degradation, means exogenous AEA doesn’t survive long enough to produce a sustained pharmacological effect in most research preparations. The field solved this problem years ago: if you want to study endocannabinoid tone, you reach for a FAAH inhibitor like URB597 or PF-04457845, not the substrate itself. As a directly administered compound, AEA scores poorly on translational signal because theres essentially nothing to translate. You can’t build a dosing study around a molecule with a half-life measured in minutes.

What saves it from the bottom of the library is bench utility. If youre running a receptor binding assay, characterizing a novel CB1 ligand, or studying FAAH enzyme kinetics, AEA is the reference standard you need. The secondary TRPV1 and PPAR-gamma activity gives it a multi-target profile that matters when you’re trying to dissect endocannabinoid signaling more broadly. A few serious labs are still working on whether CB1/TRPV1 co-activation accounts for the cleaner preclinical analgesia data coming out of the system, and that work requires AEA specifically rather than a synthetic substitute.

The endocannabinoid system remains genuinely active research territory. CB1/CB2 modulation, FAAH and MAGL inhibition strategies, and AEA’s involvement in neuroinflammation and stress signaling are live areas with real funding and real open questions. AEA sits at the center of that biology, but the research action has shifted to the pharmacological tools that modulate the system rather than to the endogenous ligand itself. We think about it the way we’d think about a high-value reference standard: indispensable for certain assays, not a compound you’d build a 2025 research program around.

Differentiation scores relatively well because AEA is the canonical endogenous CB1 agonist and cant be substituted in studies where endogenous-agonist pharmacology is the specific question. But low translational signal and modest novelty pull the overall to where it lands. Serious endocannabinoid investigators need AEA in the freezer. They’re not writing grants around it.

Novelty

35

Mechanism promise

48

In-category differentiation

58

Evidence quality

50

Translational signal

22

Research bench value

70

Rationale AEA earns solid bench-value marks as the canonical CB1 reference standard and FAAH substrate, but near-zero translational signal from FAAH-mediated rapid degradation and 33 years of mature literature pull the overall well below mid-range. The research action has migrated to FAAH inhibitors; AEA itself is the tool you measure against, not the compound you investigate.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endocannabinoid (N-arachidonoylethanolamine)

The principal endogenous CB1 receptor agonist; a fatty acid amide neurotransmitter implicated in mood, pain, and reward.

Abstract

Anandamide (N-arachidonoylethanolamine, AEA; CAS 94421-68-8; molecular formula C22H37NO2; molecular weight 347.53) is the principal endogenous CB1 receptor agonist, isolated by Devane and Mechoulam in 1992 (Nature). The name derives from the Sanskrit ananda (bliss). The compound is synthesized on-demand from membrane phospholipid precursors via NAPE-PLD and degraded primarily by fatty acid amide hydrolase (FAAH); the on-demand synthesis-degradation kinetics produce highly localized signaling without the persistent receptor occupation typical of conventional neurotransmitters. CB1 affinity is approximately 89 nM with full agonist activity; secondary TRPV1 and PPAR-gamma activity. Plasma half-life is on the order of minutes, extremely short owing to rapid FAAH-mediated degradation. Used as the canonical endocannabinoid in academic neuroscience and as a substrate in FAAH inhibitor research. The administration of exogenous anandamide as a drug is impractical owing to the short half-life; FAAH inhibitors (URB597, PF-04457845) are used to elevate endogenous anandamide instead.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-323Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
N,N-Dimethyltryptamine (N,N-DMT)

Endogenous tryptamine / 5-HT2A agonist

An endogenous tryptamine; the principal psychoactive constituent of ayahuasca; a high-affinity 5-HT2A receptor agonist.

Abstract

N,N-Dimethyltryptamine (N,N-DMT; CAS 61-50-7; molecular formula C12H16N2; molecular weight 188.27) is an endogenous and exogenous tryptamine alkaloid identified in many plants (notably Mimosa hostilis and Psychotria viridis) and at trace concentrations in mammalian tissue. The compound is the principal psychoactive constituent of ayahuasca brews, where harmala beta-carbolines provide MAO-A inhibition that allows oral DMT activity. Pharmacologically, DMT is a high-affinity full agonist at 5-HT2A (Ki approximately 75 nM), 5-HT1A, and 5-HT2C receptors with secondary activity at sigma-1, TAAR1, and other targets. Plasma half-life is extremely short (approximately 15 minutes) owing to rapid MAO-A degradation; oral administration without MAO inhibition is essentially inactive. Behavioral effects include intense visual imagery, altered sense of time, and (at higher doses) sense of communicating with autonomous entities. Approximately 30 active research and clinical trials of DMT and analogs are underway as of 2024 for depression and other psychiatric indications. Schedule I in the US under the CSA. Used as the canonical classical psychedelic in academic neuroscience.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-340Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Loratadine

Plain-language summaryIntrigue 44 / 100

Loratadine, sold as Claritin, is a second-generation antihistamine that is technically a prodrug: most of its clinical effect comes from the active metabolite desloratadine generated by the liver. Like cetirizine it stays largely peripheral, producing allergy relief without significant sedation or anticholinergic effects. It has somewhat lower H1 affinity than cetirizine but a longer duration of action, supporting once-daily dosing. The choice between loratadine, cetirizine, and fexofenadine is largely a matter of individual tolerability and onset preference. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

32/100

Canonical reference antihistamine superseded by its own metabolite; minimal research frontier value

Look, loratadine is Claritin. It’s been on pharmacy shelves since 1993, it’s been OTC since 2002, and if your grandmother has seasonal allergies she probably has a box in her medicine cabinet. That’s not a knock on the compound exactly, but it tells you everything you need to know about its position in a research library built around frontier science.

The mechanism is single-receptor competitive H1 antagonism in the peripheral compartment. That’s it. There’s no dual-target story, no allosteric angle, no novel signaling cascade. The reason it doesn’t make you sleepy is CNS impermeability, which is a pharmacokinetic feature, not a mechanistic surprise. Schering-Plough figured this out thirty years ago and the field hasn’t needed to revisit it since.

What makes the differentiation score particularly bad is that loratadine is a prodrug of desloratadine, which has roughly 250-fold higher H1 affinity (0.4 nM vs. ~100 nM) and a much longer half-life. Clarinex — desloratadine — exists. If you’re running H1 biology and you need a clean peripheral antihistamine probe, theres almost no reason to reach for loratadine over its own active metabolite. Add fexofenadine (P-gp substrate, even cleaner CNS exclusion) and cetirizine (higher affinity, different selectivity profile) and loratadine occupies a pretty awkward middle ground.

Where loratadine earns real credit is in bench value as a reference standard. The abstract correctly identifies it as the canonical non-sedating H1 antihistamine in research. If you’re characterizing a novel compound’s CNS penetration profile, or running histamine challenge experiments with a well-defined comparator, loratadine is a legitimate tool. The evidence quality and translational scores also reflect decades of well-designed trials, regulatory review across multiple jurisdictions, and extensive post-marketing data. That’s real. It’s just not interesting from a discovery standpoint.

We don’t see a novel indication story here that would change the calculus. There’s some scattered literature on mast cell involvement and inflammatory pathways beyond pure H1 blocking, but nothing with the kind of signal that would reframe this as an active frontier target. The CYP3A4/2D6 metabolism and its drug interaction profile are worth noting for stack work, not for discovery research.

Honestly, if loratadine is in your library, it’s there as a control compound and a sourcing sanity check, not because bench scientists are racing to study it. Score reflects that reality.

Novelty

12

Mechanism promise

15

In-category differentiation

12

Evidence quality

75

Translational signal

65

Research bench value

35

Rationale Loratadine’s high evidence and translational scores reflect three decades of solid clinical data, but those scores are offset heavily by near-floor novelty, mechanism, and differentiation: it is a 1993-approved OTC prodrug whose active species (desloratadine) is separately marketed and pharmacologically superior. The calculated overall of 32 lands without a hard cap binding; the score reflects a compound that functions primarily as a negative-control or reference standard rather than a genuine research target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Second-generation H1 antihistamine (peripheral)

A piperidine second-generation H1 antihistamine; a non-sedating allergy medication and the prodrug of desloratadine.

Abstract

Loratadine (ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate; CAS 79794-75-5; molecular formula C22H23ClN2O2; molecular weight 382.88) is a piperidine second-generation H1 antihistamine developed at Schering-Plough and approved by the FDA in 1993 (Claritin). H1 affinity is approximately 100 nM, lower than cetirizine but with similar peripheral selectivity (minimal CNS penetration). The principal active species is the metabolite desloratadine (formed via CYP3A4 and CYP2D6), which has higher H1 affinity (approximately 0.4 nM) and longer half-life; desloratadine is marketed separately as Clarinex. Plasma half-life of loratadine is approximately 8 hours; desloratadine half-life is approximately 27 hours. Approved indications: allergic rhinitis, urticaria. Sedation incidence is approximately 8 percent (similar to placebo in most trials), the lowest of the second-generation antihistamines. Used as the canonical non-sedating H1 antihistamine in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-357Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Edaravone

Plain-language summaryIntrigue 70 / 100

Edaravone is a small molecule that mops up free radicals (reactive oxygen species that damage neurons during stress). Mitsubishi-Tokyo developed it in Japan, where it was approved in 2001 for acute ischemic stroke. The FDA later approved it in 2017 for ALS based on a Japanese phase 3 trial showing slowed functional decline in early-stage patients with preserved breathing capacity. The benefit is real but modest, and only a subset of ALS patients qualify. An oral version arrived in 2022, replacing the original IV-only protocol. Edaravone is the canonical free-radical scavenger drug in neurology research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

FDA-approved ROS scavenger for ALS and stroke, useful reference compound but not frontier research

Look, edaravone has a genuinely interesting story on paper: a pyrazolone compound that scavenges peroxyl and hydroxyl radicals, approved in Japan for acute ischemic stroke back in 2001 and then FDA-approved for ALS in 2017 under Radicava. Thats a real clinical track record. The oral formulation (Radicava ORS) added in 2022 improved the accessibility picture considerably. So why aren’t we more excited about it?

The mechanism is the issue. Free radical scavenging as a primary MoA is one of those ideas that looks elegant until you zoom out and count how many antioxidant compounds have failed to translate in neurodegeneration trials. Oxidative stress is absolutely real in ALS pathology, and edaravone’s Japanese phase 3 (MCI186-19) did show slowed functional decline on the ALSFRS-R. But that trial enrolled a carefully selected subset: early disease, preserved respiratory function, no comorbidities that would confound. Whether the signal holds in broader populations is genuinely contested. The Japanese and US regulatory bodies accepted it; a meaningful portion of neurologists remain unconvinced of real efficacy in typical ALS patients.

As a research tool, edaravone’s strongest role is probably as the canonical ROS scavenger reference compound in neurology and ischemic injury models. If you’re running oxidative stress assays in neural cell lines or rodent stroke preparations, it’s a clean, well-characterized probe with predictable pharmacokinetics (plasma half-life around 4.5 hours). That utility is real. It’s not going to answer questions that N-acetylcysteine or MnTBAP couldn’t also probe, but the regulatory-grade characterization makes it a credible positive control in publication-facing work.

What we like: the ALS approval gives investigators a legitimate clinical hook, and edaravone is one of only two approved pharmacological options for the disease (alongside riluzole), which means it gets used in the field whether researchers are excited by the mechanism or not. The transition to oral dosing also solves some practical barriers for repeat-exposure study designs.

What we don’t like: free radical scavenging is not a frontier mechanism. That’s been the central critique of the entire antioxidant therapeutic category for decades. The subset-specificity of the phase 3 data makes translational extrapolation genuinely uncertain, and the compound itself doesn’t open any research question that other tools can’t address. Honestly, edaravone sits in the ‘approved tool with modest novelty’ bucket. Researchers in ALS biology will have it in their toolkit by necessity; investigators outside that specific indication don’t have strong reason to prioritize it over more targeted probes.

Novelty

30

Mechanism promise

28

In-category differentiation

42

Evidence quality

60

Translational signal

60

Research bench value

55

Rationale Edaravone earns its novelty and mechanism scores from a mature, crowded antioxidant class with a poor track record in broader neurodegeneration; the ALS approval via MCI186-19 is real but the carefully selected subset blunts translational confidence. Evidence and translational scores are lifted by FDA approval, but the compound firmly occupies ‘approved workhorse’ territory rather than anything a frontier investigator would reprioritize around.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Free radical scavenger

A pyrazolone free radical scavenger; approved in Japan and the US for amyotrophic lateral sclerosis (ALS) and acute ischemic stroke.

Abstract

Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one; CAS 89-25-8; molecular formula C10H10N2O; molecular weight 174.20) is a pyrazolone free radical scavenger developed at Mitsubishi-Tokyo Pharmaceuticals. Originally approved in Japan in 2001 for acute ischemic stroke (Radicut), and in 2017 approved by the FDA for amyotrophic lateral sclerosis (Radicava). Mechanism: edaravone scavenges peroxyl, hydroxyl, and other reactive oxygen species, reducing oxidative damage to neurons and the surrounding glia in the affected region. The ALS approval was supported by a Japanese phase 3 trial (MCI186-19) demonstrating slowed functional decline (ALSFRS-R score) in a subset of patients with early disease and preserved respiratory function. Initially IV-only; an oral formulation (Radicava ORS) was approved in 2022. Plasma half-life is approximately 4.5 hours. Used as the canonical free radical scavenger in neurology research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-372Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Progesterone (Research)

Plain-language summaryIntrigue 65 / 100

Progesterone is the principal endogenous progestogen, built from cholesterol via pregnenolone in the corpus luteum, adrenal cortex, and (in pregnancy) placenta. It activates the progesterone receptor with high affinity and also has interesting side effects: it antagonizes mineralocorticoid receptors (driving sodium loss) and its metabolite allopregnanolone is a powerful positive modulator of GABA-A receptors (driving sedation). Approved for menopausal hormone therapy paired with estrogen for endometrial protection, IVF luteal support, secondary amenorrhea, and preterm birth prevention. Oral micronized progesterone hits the liver hard and produces sedating allopregnanolone, while vaginal and transdermal forms give cleaner PR effects. Plasma half-life of the parent is short (5 to 20 minutes). Canonical PR agonist. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

48/100

Canonical endogenous PR agonist; mature approved-drug evidence base, low novelty, infrastructure-grade bench tool

Look, progesterone is the compound you already have on the bench before you start designing experiments. It’s the canonical endogenous progestogen, the reference PR agonist against which everything else in its class gets compared. That’s a real and meaningful role. It’s just not what makes something an exciting research target in 2026.

The mechanism is worth unpacking because its actually more layered than the single-receptor framing suggests. High-affinity PR agonism drives the reproductive and endometrial effects everyone knows. Weak glucocorticoid receptor activity produces a mineralocorticoid-antagonist fingerprint that contributes to natriuretic effects. And first-pass hepatic conversion to allopregnanolone produces GABA-A positive allosteric modulation — which is why oral micronized progesterone (Prometrium) reliably produces sedation in a way vaginal forms don’t. That last piece is where the most interesting current biology lives. Brexanolone, which is essentially IV allopregnanolone, got FDA approval for postpartum depression in 2019, and the neurosteroid GABA-A PAM space is genuinely active right now. But the excitement is about synthetic neurosteroid analogs — zuranolone, ganaxolone, next-generation GABA-A selective compounds. Progesterone the compound is upstream infrastructure for that story, not the lead character.

The evidence base is as mature as it gets for a non-blockbuster pharmaceutical. Multiple phase 3 RCTs, approved across HRT, assisted reproductive technology, secondary amenorrhea, and intramuscular preterm birth prevention. The translational arrow is solid for those established uses. Where it gets instructive: the TBI neuroprotection story once looked promising. ProTECT II phase 2 showed signal, the mechanistic rationale was plausible, and then the ProTECT III trial was definitively negative. That failure matters — it’s a clean example of how compelling preclinical work and early phase 2 signal can collapse under a well-powered phase 3, and it appropriately cooled enthusiasm for progesterone as a neuroprotective research target.

For bench use, progesterone is straightforward infrastructure. It’s the reference standard for PR biology, reproductive physiology studies, and neurosteroid pathway work. Sourcing is genuinely easy — multiple suppliers with USP/EP-grade material, well-characterized reference standards widely available. Reconstitution for in vitro work is routine in ethanol or DMSO. Nothing technically demanding here.

What we dont love: novelty is essentially nil for the compound itself in 2026. The frontier science is at the level of synthetic neurosteroid analogs and selective PR modulators, not progesterone as a primary investigational compound. If you’re building a research program, progesterone is part of your toolkit, not your lead. It earns its place as a reference standard and a component of neurosteroid pathway studies, but it’s not where you’d place your exploratory bets. Score accordingly.

Novelty

20

Mechanism promise

40

In-category differentiation

45

Evidence quality

72

Translational signal

68

Research bench value

60

Rationale Progesterone is the reference-standard PR agonist with a thoroughly characterized multi-receptor pharmacology (PR, weak GR, GABA-A via allopregnanolone metabolite) and an approved-drug evidence base spanning HRT, ART, and preterm birth prevention. The interesting neurosteroid science has largely migrated to synthetic analogs like zuranolone and ganaxolone; progesterone itself scores low on novelty and differentiation, pulling the overall to 48 despite solid evidence and translational signal.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous progestogen / PR agonist

The principal endogenous progestogen; a progesterone receptor agonist with luteal phase, gestational, and neurosteroid functions.

Abstract

Progesterone (pregn-4-ene-3,20-dione; CAS 57-83-0; molecular formula C21H30O2; molecular weight 314.46) is the principal endogenous progestogen, biosynthesized from cholesterol via pregnenolone in the corpus luteum, adrenal cortex, and (during pregnancy) placenta. The compound is a high-affinity progesterone receptor (PR) agonist with secondary effects at the glucocorticoid receptor (mineralocorticoid antagonism contributing to natriuretic effects) and at GABA-A receptors (the pregnanolone metabolite is a positive allosteric modulator producing sedation). Approved indications: menopausal hormone therapy (combined with estrogen for endometrial protection in women with intact uterus), assisted reproductive technology luteal support, secondary amenorrhea, and prevention of preterm birth (intramuscular formulation). Oral micronized progesterone (Prometrium) is highly subject to first-pass metabolism producing the sedating allopregnanolone metabolite; vaginal and transdermal forms produce more direct PR effects with less sedation. Plasma half-life is short (5 to 20 minutes for parent; metabolites variable). Used as the canonical PR agonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-388Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Donepezil

Plain-language summaryIntrigue 75 / 100

Donepezil, sold as Aricept, is the most prescribed acetylcholinesterase inhibitor for Alzheimer disease. It selectively raises brain acetylcholine to compensate for cholinergic neuron loss in dementia. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

Mature gold-standard AChE inhibitor with unmatched clinical data but negligible research novelty

Look, donepezil is the reference standard for its entire drug class and thats not nothing. Thirty years of clinical data, FDA approval across three dementia subtypes, better pharmacokinetics than anything else in the AChE inhibitor family. If you’re building a research program around cholinergic pharmacology, donepezil is the tool you reach for to establish a benchmark. That’s genuine bench value and we’re crediting it.

Here’s the thing though: the mechanism is a single, thoroughly characterized enzyme inhibition. Acetylcholinesterase is not a frontier target. The cholinergic hypothesis of Alzheimer disease has been researched continuously since the early 1980s, and donepezil is its most refined expression. The greater-than-1000-fold selectivity over butyrylcholinesterase is impressive engineering, but it doesn’t add new pharmacology. You get more ACh at the synapse. That’s it. The compound has essentially no significant secondary receptor activities at therapeutic concentrations, and the clean profile that makes it clinically useful is the same thing that makes it mechanistically uninteresting.

The clinical picture reinforces the research picture. Multiple Phase 3 RCTs confirm real, consistent effects on ADAS-cog and MMSE in Alzheimer populations. The effects are small, symptomatic, and non-disease-modifying. The field’s attention has largely moved toward amyloid-directed biologics, tau pathology, and neuroinflammation. Donepezil sits on the approved-drug shelf while the genuinely interesting work happens elsewhere.

There are niche angles that keep donepezil relevant as a tool: some groups are probing sigma-1 receptor co-pharmacology, and the cognitive-enhancement literature in healthy subjects occasionally runs donepezil as a comparator or probe. Recent interest in Lewy body dementia and sleep architecture represents maybe the most active current fringe. None of those are sufficient to move the novelty needle in a meaningful way.

What we like: the pharmacokinetics are genuinely excellent for a research setting. Once-daily oral dosing, essentially complete bioavailability, clean hepatic metabolism via CYP2D6 and CYP3A4. If you need a cholinergic reference compound, donepezil is the professional choice. What we don’t like for a research library context: you’re not going to answer a new question with it. The mechanism is characterized, the population response is characterized, and the ceiling on what AChE inhibition can do in humans has been fairly well defined by decades of modest-but-real phase 3 results.

Overall, donepezil earns its place as a serious reference tool, and the evidence base is one of the strongest in this library. But it’s not a frontier compound. This is mature, proven cholinergic pharmacology, and the score reflects that honestly.

Novelty

20

Mechanism promise

28

In-category differentiation

50

Evidence quality

82

Translational signal

68

Research bench value

50

Rationale Donepezil leads its class on selectivity and evidence depth, but the mechanism is a single well-characterized enzyme inhibition exhaustively studied for three decades; high evidence and translational scores are offset by minimal novelty and mechanism promise, placing this squarely in the mature-but-uninspiring tier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective acetylcholinesterase inhibitor

A piperidine-class selective reversible acetylcholinesterase inhibitor, FDA-approved as Aricept for Alzheimer disease, with the largest clinical evidence base of the AChE inhibitor class.

Abstract

Donepezil (Aricept; (R/S)-2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one hydrochloride; CAS 120014-06-4; molecular formula C24H29NO3; molecular weight 379.49) is a piperidine-class selective reversible acetylcholinesterase inhibitor developed by Eisai and approved by the FDA in 1996 for mild, moderate, and severe Alzheimer disease. The compound has the highest AChE selectivity (over 1000-fold versus butyrylcholinesterase) of the marketed AChE inhibitors and a long plasma half-life (70 hours) that supports once-daily dosing. Mechanism is selective AChE inhibition without significant secondary activities at nicotinic receptors or other targets. The clinical evidence base in Alzheimer disease is extensive; multiple Phase 3 trials demonstrate small but consistent improvements in cognitive endpoint measures (ADAS-cog, MMSE) and global functional status. The compound is also approved for vascular dementia and Parkinson disease dementia in some jurisdictions. Pharmacokinetics: oral bioavailability essentially complete; metabolism is hepatic via CYP2D6 and CYP3A4 with minor active metabolites. Approved doses are 5 to 23 mg per day; the 23 mg formulation was approved in 2010 for severe Alzheimer disease. Schedule status: prescription-only but not federally scheduled.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-046Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Resveratrol

Plain-language summaryIntrigue 60 / 100

Resveratrol is a natural compound found in red wine, grape skins, and Japanese knotweed. It activates sirtuins and other longevity-associated pathways and has been the subject of intense longevity research. Oral bioavailability is poor, limiting clinical efficacy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundOverhyped vs evidence

30/100

Well-studied polyphenol undermined by poor bioavailability and a partially-discredited SIRT1 narrative

Look, resveratrol had its moment. David Sinclair’s 2003 Cell paper on SIRT1 activation was genuinely exciting, and the follow-up 2006 Nature paper showing lifespan extension in obese mice turned this grape polyphenol into one of the most-hyped compounds in aging biology. The problem is that most of that story has since unraveled in ways that matter for bench work.

The SIRT1 activation mechanism (the whole foundation of the resveratrol narrative) turned out to be substrate-dependent. The original assay used an artificial fluorophore-tagged substrate, and when Pfizer’s group and others replicated with native peptide substrates, the activation was dramatically reduced or absent. SIRT1 activation is real in some substrate contexts but the claim that resveratrol is a general SIRT1 activator doesn’t hold up. That’s not a minor quibble; it’s the central claim. The compound still hits AMPK and NF-kB, and the antioxidant activity is real, but none of those targets are unique to resveratrol and none of them explain the original hype.

Bioavailability is the other killer. Oral resveratrol undergoes rapid phase-2 conjugation and first-pass metabolism, leaving plasma concentrations that are typically one to ten percent of what drives effects in cell culture. The human dose to hit effective tissue concentrations either isn’t achievable or requires doses that create their own tolerability issues. This isn’t new information; it’s been known since the early 2010s. It means that most clinical trials were essentially testing whether resveratrol works at sub-therapeutic concentrations. The answer, unsurprisingly, has been mostly no.

The clinical trial record reinforces this. The CALERIE-adjacent work, the trials in diabetic and metabolic patients, the cardiovascular studies: effect sizes are modest at best, null at worst. Resveratrol supplementation in otherwise healthy populations shows very little. There are some positive signals in specific subpopulations (older adults, high-fat-diet stress conditions) but nothing close to what the preclinical story implied, and the lifespan extension in mice failed to replicate in normally-fed animals.

What we don’t like about resveratrol as a research target right now: the field has genuinely moved on. If you’re interested in the sirtuin axis, NMN and NR have better pharmacokinetics and a more credible human signal. If you want a stilbenoid probe, pterostilbene has improved bioavailability and a tighter mechanistic story. If you want a polyphenol tool for NF-kB or antioxidant pathway work, there are cleaner options. Resveratrol still appears in bench protocols as a positive control for antioxidant assays and as a historical comparator in aging studies, and thats a legitimate use case. But it’s not where you’d anchor a research program in 2025. The hype-to-evidence ratio here is one of the worst in the longevity compound space, and that’s saying something.

Novelty

22

Mechanism promise

30

In-category differentiation

20

Evidence quality

52

Translational signal

22

Research bench value

40

Rationale Resveratrol scores low on novelty and differentiation because the flagship SIRT1 activation story is now known to be substrate-artifact-dependent, and the compound has been largely superseded by NMN/NR on the sirtuin axis and pterostilbene in the stilbenoid space; a large clinical trial base exists but mostly returns null results at achievable plasma concentrations, killing the translational score.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Stilbenoid polyphenol / sirtuin modulator

A trans-stilbenoid polyphenol from grapes and other plants, characterized by SIRT1 activation and pleiotropic anti-aging effects with disputed clinical efficacy.

Abstract

Resveratrol (trans-3,4′,5-trihydroxystilbene; CAS 501-36-0; molecular formula C14H12O3; molecular weight 228.25) is a stilbenoid polyphenol present in grapes, peanuts, berries, and several other plants. The compound has been extensively studied for anti-aging applications since David Sinclair’s group at Harvard demonstrated SIRT1 activation in 2003. Mechanism includes SIRT1 sirtuin activation (allosteric activator at certain peptide substrates; the activity is substrate-dependent), AMPK activation, anti-inflammatory effects through NF-kB inhibition, and direct antioxidant activity. Resveratrol extends lifespan in obese mice and in some short-lived model organisms but does not extend lifespan in normally fed mice; the lifespan-extending effect appears to be selective for high-fat-diet stress conditions. Bioavailability is poor (high first-pass metabolism); plasma resveratrol concentrations after oral administration are typically 1 to 10 percent of those that produce in vitro effects. Doses are typically 250 to 1500 mg per day. The clinical evidence base in humans is mixed; many endpoints show no effect at achievable plasma concentrations.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-097Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Panax Ginseng

Plain-language summaryIntrigue 55 / 100

Panax ginseng is the original Asian ginseng, used in traditional medicine for thousands of years. Ginsenosides drive the energy, cognitive, and stress-resistance effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

34/100

Heavily studied classical adaptogen with real but modest clinical signals, poorly suited to mechanistic bench work as a whole extract

Look, Panax ginseng is the most-studied plant adaptogen on the planet. Thats not nothing. Ginsenosides like Rg1 and Rb1 have a genuinely complex pharmacology: stimulant-like profiles at some receptor targets, sedating through others, immunomodulatory across yet another set. The whole-extract story isnt clean, and that complexity is actually the compound’s biggest problem as a bench target.

Here’s the thing: if you want to study ginsenoside biology in 2025, you’re almost certainly going to work with isolated compounds, not whole root extract. Individual ginsenosides have more tractable pharmacology and cleaner mechanistic stories. Rg1 has received targeted attention for hippocampal neurogenesis and VEGF expression; Rb1 has a separate literature around neuroprotection via BDNF modulation. Those are genuinely more interesting research objects than the parent extract, and we’d rather see a library entry for one of them than for the whole root.

The clinical literature on whole-extract Panax ginseng is real but frustrating. Multiple RCTs document modest cognitive benefits (working memory, reaction time, fatigue reduction) and there’s credible evidence for erectile function and some immune endpoints. But effect sizes are rarely decisive and the trial heterogeneity is substantial: different extract profiles, different ginsenoside standardizations, different dose windows. The 2010 Cochrane review on cognitive function found some support but called the evidence insufficient for firm conclusions, and not much has shifted that calculus in the years since.

What we dont love is the translational uncertainty baked into a multi-component extract with competing agonist and antagonist activities at overlapping targets. Some ginsenosides upregulate NO synthase, others modulate ERK/MAPK signaling, others engage nuclear estrogen receptors at pharmacological concentrations. When you’re trying to attribute a human outcome to a defined mechanism, whole ginseng is a difficult read. The CYP interactions (CYP3A4, CYP2D6) are well-characterized and worth flagging for stack-interaction contexts, but thats advisory value, not discovery value.

Sourcing is easy. Standardized extracts at 4 to 7 percent ginsenosides are widely available and reproducible enough for preclinical work. We’re not dismissing the compound outright. There’s real signal here and a legitimate place in a reference library. But for bench researchers looking for mechanistically tractable targets with real discovery upside, the isolated ginsenoside fractions are where the interesting questions live. The whole extract scores where it does because the novelty ceiling is essentially at the floor, the mechanism story is multifaceted to the point of muddiness, and the bench utility case is significantly stronger for its own components than for the parent compound.

Novelty

22

Mechanism promise

35

In-category differentiation

30

Evidence quality

48

Translational signal

47

Research bench value

28

Rationale Panax ginseng has a genuine multi-decade clinical record across several endpoints but scores low on novelty and bench utility because the whole-extract format obscures mechanism, and isolated ginsenosides are the more tractable research objects; the OTC-herb cap (35) technically applies to the category but does not bind given the raw calculated score of 34.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Asian ginseng adaptogen

The classical Asian ginseng root with documented cognitive and metabolic effects mediated through ginsenoside saponins.

Abstract

Panax ginseng (Asian or Korean ginseng) is the most studied of the Panax genus, with millennia of traditional use in East Asian medicine. The active constituents are ginsenosides (Rg1, Rb1, Rb2, Rd, Re, Rf, and others), triterpene saponins with diverse pharmacological activities. The compound has documented modest effects on cognitive function (working memory, attention), fatigue, immune function, and erectile function. Mechanism is highly variable across ginsenosides (some are CNS stimulant-like, others sedating; some immunomodulatory, others not), making whole-extract pharmacology multifaceted. Doses are typically 200 to 600 mg of standardized extract (4 to 7 percent ginsenosides) per day. The compound interacts with many drugs through CYP modulation.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-113Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Thymopentin

Plain-language summaryIntrigue 50 / 100

Thymopentin is a 5-amino-acid synthetic peptide representing the active region of thymopoietin. Used historically for psoriasis and immune modulation. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

A mature thymic pentapeptide with real approvals but overshadowed by thymosin alpha-1 across every meaningful axis

Look, thymopentin is a legitimate compound. Arg-Lys-Asp-Val-Tyr, five residues that happen to capture most of thymopoietin’s functional activity in a peptide you can synthesize cleanly and administer subcutaneously. It’s approved in Italy under the Timunox brand, approved in China and several other Asian markets for primary immunodeficiency and hepatitis B support, and has been used in clinical practice for decades. That’s not nothing. The compound is real, the mechanism is real, the human data is real.

The problem is context. When you look at where the thymic peptide space actually sits today, thymopentin is the compound you consider before you remember that thymosin alpha-1 exists. Zadaxin has broader regulatory approval, a more extensive multi-center trial base, better-characterized cytokine kinetics, and a cleaner reputation in the literature. If youre building a research program around thymic biology and T-cell maturation, thymopentin isnt where you start. It’s where you end up if thymosin alpha-1 is unavailable or if you have a specific reason to work with the thymopoietin fragment specifically.

The mechanism is genuinely interesting in principle: the compound appears to promote thymocyte maturation, modulates the CD4/CD8 ratio, and has documented NK cell effects. We don’t dismiss that. But the biology here is well-trodden 1980s immunopharmacology. The trials supporting its approvals predate modern RCT standards. Most of the published literature comes from the era when open-label studies in Eastern European and Asian centers were the standard of evidence, and replication across independent Western lab groups is thin.

What we find most limiting is the differentiation story. The thymic peptide category has a clear hierarchy, and thymopentin isn’t at the top. Thymosin alpha-1 outperforms it on evidence density, indication breadth, and regulatory reach. Thymosin beta-4 fragments occupy a different but increasingly interesting niche. Thymopentin sits in the middle: approved, real, known, but not best-in-class on any axis that matters for a serious research prioritization decision in 2025.

There is some bench value here. If you’re specifically investigating the thymopoietin receptor axis, or studying the minimal active fragment hypothesis in thymic hormone biology, thymopentin is the obvious probe. The five-residue sequence is well-defined and commercially available from reputable peptide vendors, which matters for reproducibility. We think this is where its research merit is most defensible: as a structural probe for a well-mapped biology, not as a frontier target. Honest assessment puts it in the established-mature bucket, useful but not urgent, and a distant second to the compounds that have pushed this field forward more recently.

Novelty

32

Mechanism promise

38

In-category differentiation

25

Evidence quality

48

Translational signal

52

Research bench value

40

Rationale Thymopentin has genuine regulatory standing in Italy and several Asian markets, which pushes evidence and translational scores above peptides stuck in preclinical purgatory, but it sits squarely behind thymosin alpha-1 on differentiation and behind newer immunomodulatory targets on novelty. The thymic peptide biology is real and the pentapeptide design is elegant, but this is 1980s-era pharmacology competing in a field that has moved on.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic pentapeptide of thymopoietin

A synthetic pentapeptide fragment (residues 32-36) of thymopoietin marketed in Europe and Asia for immunomodulation in chronic infections and autoimmune disease.

Abstract

Thymopentin (Timunox, TP-5; Arg-Lys-Asp-Val-Tyr; CAS 69558-55-0; molecular weight 679.78) is a synthetic pentapeptide corresponding to residues 32-36 of thymopoietin, a thymic hormone. The fragment retains the immunomodulatory activity of full-length thymopoietin. The compound is approved in Italy and several Asian countries for primary immunodeficiency, hepatitis B, atopic dermatitis adjunct, and autoimmune disease support. Mechanism includes T-cell maturation, NK cell modulation, and cytokine balance effects. Administered subcutaneously. Doses are 50 mg three times weekly in clinical use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-130Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
N-Acetyl-L-Tyrosine

Plain-language summaryIntrigue 42 / 100

N-acetyl-L-tyrosine (NALT) is the acetylated form of tyrosine, marketed as more bioavailable than free tyrosine. Evidence for the bioavailability claim is limited but the compound is widely used in nootropic formulations. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundOverhyped vs evidence

11/100

Disproven bioavailability claim makes NALT strictly inferior to plain L-tyrosine as a research substrate

Look, we’ll be direct: NALT is essentially a marketing artifact. The pitch has always been that acetylation improves tyrosine’s bioavailability and CNS penetration, making it a smarter substrate for catecholamine synthesis than plain L-tyrosine. The problem is that human pharmacokinetic data doesn’t support this. Tissue deacetylases do convert NALT to free tyrosine, but the efficiency is poor enough that a substantial fraction of the administered dose is excreted as intact NALT in urine without ever contributing to tyrosine pools. You’re not getting more tyrosine to the brain; you’re getting less tyrosine to anywhere, with the difference ending up in the toilet.

This isn’t a subtle finding or a contested edge case. The PK literature is pretty clear: L-tyrosine itself achieves better plasma tyrosine elevation on an equal milligram basis. The acetylated form was supposed to behave as a pro-drug that shed its acetyl group efficiently in peripheral tissue. It doesn’t. Thats the whole story.

From a research standpoint, theres almost nothing useful here. If your question involves catecholamine substrate loading, you want L-tyrosine. If your question involves measuring how specific deacetylase activity affects amino acid bioavailability, NALT could theoretically serve as a narrow probe substrate, but that’s an extremely specific experimental design and not a general research tool. We don’t know of serious research programs using NALT for that purpose, and we wouldn’t expect to find them.

The mechanism column is equally thin. Catecholamine synthesis from tyrosine via tyrosine hydroxylase is foundational biochemistry understood for decades. There’s no novel angle here, no dual-target story, no surprising receptor biology. It’s a substrate for a well-understood pathway, and it’s a worse substrate than the unmodified amino acid. That combination, unremarkable mechanism plus inferior pharmacokinetics, is about as uncompelling as a research compound gets.

Differentiation is near zero, and it’s negative where it matters. NALT competes directly with L-tyrosine in the catecholamine support space and loses on PK grounds. It also competes with phenylalanine as an upstream precursor, and loses there too. We can’t identify a single application where NALT is the correct choice over a readily available comparator.

Honestly, this is one of the cleaner examples of supplement marketing outrunning the science. The acetylation story sounded plausible, vendors ran with it for years, and the actual PK work eventually showed the premise was wrong. Its still widely sold. Researchers looking at catecholamine biology should skip NALT entirely and work with L-tyrosine directly. Nothing here to chase.

Novelty

8

Mechanism promise

7

In-category differentiation

8

Evidence quality

25

Translational signal

10

Research bench value

12

Rationale NALT’s core premise, that acetylation improves CNS delivery of tyrosine, is contradicted by human PK data showing poor deacetylation and urinary excretion of intact NALT; all six axes score near floor because the compound is demonstrably worse than its unmodified comparator and carries no compensating research utility.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Acetylated tyrosine

An N-acetylated form of L-tyrosine with claimed superior bioavailability that has not been validated in pharmacokinetic studies.

Abstract

N-Acetyl-L-Tyrosine (NALT) is an N-acetylated form of L-tyrosine sold as a dietary supplement with claims of improved bioavailability and CNS penetration compared with L-tyrosine itself. Pharmacokinetic studies in humans show that NALT is poorly converted to free tyrosine by tissue deacetylases (the bulk is excreted as NALT in urine without contributing to tyrosine pools). The compound is therefore likely to be inferior to L-tyrosine on a milligram basis for catecholamine support applications, despite vendor claims. Investigators should generally use L-tyrosine itself.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-146Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 51 52 53 54 55 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.